Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study

EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology

(2022) Delphine Sophie Courvoisier et al.   ANNALS OF THE RHEUMATIC DISEASES

Humoral immunogenicity of COVID-19 vaccines in patients with inflammatory rheumatic diseases under treatment with Rituximab: a case–control study (COVID-19VacRTX)

(2022) Falk Schumacher et al.   RHEUMATOLOGY

Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses

(2022) Benazir Saleem et al.   RMD Open

SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry

(2022) Jean Liew et al.   RMD Open

Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies

(2022) Laura Boekel et al.   Lancet Rheumatology

Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: a cohort study from OpenSAFELY

(2022) et al.   BMC Medicine

Breakthrough SARS‐CoV‐2 infections in immune mediated disease patients undergoing B cell depleting therapy: A retrospective cohort analysis

(2022) Cassandra M Calabrese et al.   Arthritis & Rheumatology

Predictors of Immunogenic Response to the BNT162b2 mRNA COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases Treated with Rituximab

(2022) Victoria Furer et al.   Vaccines

Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunity

(2022) Cassandra Calabrese et al.   RMD Open

Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

(2021) Anja Strangfeld et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2

(2021) Parakkal Deepak et al.   ANNALS OF INTERNAL MEDICINE

Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

(2021) Jeffrey A Sparks et al.   ANNALS OF THE RHEUMATIC DISEASES

Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression

(2021) Maria Prendecki et al.   ANNALS OF THE RHEUMATIC DISEASES

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study

(2021) Victoria Furer et al.   ANNALS OF THE RHEUMATIC DISEASES

B-cell targeted therapy is associated with severe COVID-19 among patients with inflammatory arthritides: a 1-year multicentre study in 1116 successive patients receiving intravenous biologics

(2021) Renaud Felten et al.   ANNALS OF THE RHEUMATIC DISEASES

SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity

(2021) Daniel Mrak et al.   ANNALS OF THE RHEUMATIC DISEASES

Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study

(2021) Matthias B Moor et al.   Lancet Rheumatology

COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

(2021) Jérôme Avouac et al.   Lancet Rheumatology

Risk factors of impaired humoral response to COVID-19 vaccination in rituximab-treated patients

(2021) Jérôme Avouac et al.   RHEUMATOLOGY

Rituximab impairs B‐cell response but not T‐cell response to COVID ‐19 vaccine in auto‐immune diseases

(2021) Samuel Bitoun et al.   Arthritis & Rheumatology

A minimal common outcome measure set for COVID-19 clinical research

(2020) John C Marshall et al.   LANCET INFECTIOUS DISEASES

Predicting severe infection and effects of hypogammaglobulinaemia during therapy with rituximab in rheumatic and musculoskeletal diseases

(2019) Md Yuzaiful Md Yusof et al.   Arthritis & Rheumatology

OUP accepted manuscript

(2017)   RHEUMATOLOGY

Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years

(2015) R. F. van Vollenhoven et al.   JOURNAL OF RHEUMATOLOGY

Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0

(2014) Tatiana Cobo-Ibáñez et al.   RHEUMATOLOGY INTERNATIONAL

Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients

(2014) Joerg Wendler et al.   ARTHRITIS RESEARCH & THERAPY

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)

(2011) Hans-Peter Tony et al.   ARTHRITIS RESEARCH & THERAPY

Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry

(2010) J.-E. Gottenberg et al.   ARTHRITIS AND RHEUMATISM

Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry

(2010) Benjamin Terrier et al.   ARTHRITIS AND RHEUMATISM

Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis

(2008) Shouvik Dass et al.   ARTHRITIS AND RHEUMATISM